Second messengers and their importance for novel drug treatments of patients with bipolar disorder

References

• Andreazza, A. C., Gildengers, A., Rajji, T. K., Zuzarte, P. M., Mulsant, B. H., & Young, L. T. (2015). Oxidative stress in older patients with bipolar disorder. The American Journal of Geriatric Psychiatry, 23(3), 314–319. doi:10.1016/j.jagp.2014.05.008
   PubMed Web of Science ®Google Scholar
• Atack, J. R. (1995). Inositol monophosphatase inhibitors: A novel treatment for bipolar disorder? Biological Psychiatry, 37(11), 761–763. doi:10.1016/0006-3223(95)00020-H
   PubMed Web of Science ®Google Scholar
• Bachmann, R. F., Schloesser, R. J., Gould, T. D., & Manji, H. K. (2005). Mood stabilizers target cellular plasticity and resilience cascades: Implications for the development of novel therapeutics. Molecular Neurobiology, 32(2), 173–202. doi:10.1385/MN:32:2:173
   PubMed Web of Science ®Google Scholar
• Begemann, M., Sargin, D., Rossner, M. J., Bartels, C., Theis, F., Wichert, S. P., Stender, N., Fischer, B., Sperling, S., Stawicki, S., Wiedl, A., Falkai, P., Nave, K. A., & Ehrenreich, H. (2008). Episode-specific differential gene expression of peripheral blood mononuclear cells in rapid cycling supports novel treatment approaches. Molecular Medicine, 14(9–10), 546–552. doi:10.2119/2008-00053.Begemann
   PubMed Web of Science ®Google Scholar
• Behl, T., Kotwani, A., Kaur, I., & Goel, H. (2015). Mechanisms of prolonged lithium therapy-induced nephrogenic diabetes insipidus. European Journal of Pharmacology, 755, 27–33. doi:10.1016/j.ejphar.2015.02.040
   PubMed Web of Science ®Google Scholar
• Bertolino, A., Crippa, D., di Dio, S., Fichte, K., Musmeci, G., Porro, V., Rapisarda, V., Sastre-y-Hernández, M., & Schratzer, M. (1988). Rolipram versus imipramine in inpatients with major, “minor” or atypical depressive disorder: A double-blind double-dummy study aimed at testing a novel therapeutic approach. International Clinical Psychopharmacology, 3(3), 245–253. doi:10.1097/00004850-198807000-00006
   PubMed Web of Science ®Google Scholar
• Bobon, D., Breulet, M., Gerard-Vandenhove, M. A., Guiot-Goffioul, F., Plomteux, G., Sastre-y-Hernández, M., Schratzer, M., Troisfontaines, B., von Frenckell, R., & Wachtel, H. (1988). Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double-dummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives. European Archives of Psychiatry and Neurological Sciences, 238(1), 2–6. doi:10.1007/BF00381071
   PubMedGoogle Scholar
• Brennan, B. P., Hudson, J. I., Jensen, J. E., McCarthy, J., Roberts, J. L., Prescot, A. P., Cohen, B. M., Pope, H. G., Jr, Renshaw, P. F., & Ongür, D. (2010). Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole. Neuropsychopharmacology, 35(3), 834–846. doi:10.1038/npp.2009.191
   PubMed Web of Science ®Google Scholar
• Cade, J. F. (1949). Lithium salts in the treatment of psychotic excitement. The Medical Journal of Australia, 2(10), 349–352. doi:10.1080/j.1440-1614.1999.06241.x
   PubMed Web of Science ®Google Scholar
• Centorrino, F., Fogarty, K. V., Sani, G., Salvatore, P., Cimbolli, P., & Baldessarini, R. J. (2005). Antipsychotic drug use: McLean Hospital, 2002. Human Psychopharmacology, 20(5), 355–358. doi:10.1002/hup.700
   PubMed Web of Science ®Google Scholar
• Drummond, G. I., & Perrott-Yee, S. (1961). Enzymatic hydrolysis of adenosine 3′,5′-phosphoric acid. The Journal of Biological Chemistry, 236, 1126–1129. doi:10.1016/S0021-9258(18)64253-X
   PubMed Web of Science ®Google Scholar
• Fibiger, H. C. (2012). Psychiatry, the pharmaceutical industry, and the road to better therapeutics. Schizophrenia Bulletin, 38(4), 649–650. doi:10.1093/schbul/sbs073
   PubMed Web of Science ®Google Scholar
• Fieblinger, T., Perez-Alvarez, A., Lamothe-Molina, P. J., Gee, C. E., & Oertner, T. G. (2022). Presynaptic cGMP sets synaptic strength in the striatum and is important for motor learning. EMBO Reports, 23(8), e54361. doi:10.15252/embr.202154361
   PubMed Web of Science ®Google Scholar
• Furlotti, G., Alisi, M. A., Cazzolla, N., Dragone, P., Durando, L., Magarò, G., Mancini, F., Mangano, G., Ombrato, R., Vitiello, M., Armirotti, A., Capurro, V., Lanfranco, M., Ottonello, G., Summa, M., & Reggiani, A. (2015). Hit Optimization of 5 substituted-N-(piperidin-4-ylmethyl)-1H-indazole-3-carboxamides: Potent glycogen synthase kinase-3 (GSK-3) Inhibitors with in vivo activity in model of mood disorders. Journal of Medicinal Chemistry, 58(22), 8920–8937. doi:10.1021/acs.jmedchem.5b01208
   PubMed Web of Science ®Google Scholar
• Garrido-Mesa, N., Zarzuelo, A., & Galvez, J. (2013). Minocycline: Far beyond an antibiotic. British Journal of Pharmacology, 169(2), 337–352. doi:10.1111/bph.12139
   PubMed Web of Science ®Google Scholar
• Geddes, J. R., Burgess, S., Hawton, K., Jamison, K., & Goodwin, G. M. (2004). Long-term lithium therapy for bipolar disorder: Systematic review and meta-analysis of randomized controlled trials. The American Journal of Psychiatry, 161(2), 217–222. doi:10.1176/appi.ajp.161.2.217
   PubMed Web of Science ®Google Scholar
• Ghaemi, S. N. (2014). DSM-5 and the miracle that never happens. Acta Psychiatrica Scandinavica, 129(6), 410–412. doi:10.1111/acps.12263
   PubMed Web of Science ®Google Scholar
• Ghaemi, S. N. (2022). Psychiatric drugs are symptomatic not disease-modifying, unpublished manuscript.
   Google Scholar
• Gong, L., Thorn, C. F., Bertagnolli, M. M., Grosser, T., Altman, R. B., & Klein, T. E. (2012). Celecoxib pathways: Pharmacokinetics and pharmacodynamics. Pharmacogenetics and Genomics, 22(4), 310–318. doi:10.1097/FPC.0b013e32834f94cb
   PubMed Web of Science ®Google Scholar
• Gould, T. D., Quiroz, J. A., Singh, J., Zarate, C. A., & Manji, H. K. (2004). Emerging experimental therapeutics for bipolar disorder: Insights from the molecular and cellular actions of current mood stabilizers. Molecular Psychiatry, 9(8), 734–755. doi:10.1038/sj.mp.4001518
   PubMed Web of Science ®Google Scholar
• Guiot-Goffioul, F., Gerard-Vandenhove, M. A., Troisfontaines, B., Breulet, M., von Frenckell, R., & Bobon, D. (1987). Résultats préliminaires d‘une étude en double aveugle entre le rolipram et la désipramine chez des déprimés majeurs hospitalisés [Preliminary results of a double-blind study between rolipram and desipramine in hospitalized patients with major depressive symptoms]. Acta Psychiatr Belg, 87(2), 230–235.
   PubMedGoogle Scholar
• Hardman, J. G., & Sutherland, E. W. (1969). Guanyl cyclase, an enzyme catalyzing the formation of guanosine 3′,5′-monophosphate from guanosine trihosphate. The Journal of Biological Chemistry, 244(23), 6363–6370. doi:10.1016/S0021-9258(18)63473-8
   PubMed Web of Science ®Google Scholar
• Hebenstreit, G. F., Fellerer, K., Fichte, K., Fischer, G., Geyer, N., Meya, U., Sastre-y-Hernández, M., Schöny, W., Schratzer, M., & Soukop, W. (1989). Rolipram in major depressive disorder: Results of a double-blind comparative study with imipramine. Pharmacopsychiatry, 22(4), 156–160. doi:10.1055/s-2007-1014599
   PubMed Web of Science ®Google Scholar
• Husain, M. I., Chaudhry, I. B., Khoso, A. B., Husain, M. O., Hodsoll, J., Ansari, M. A., Naqvi, H. A., Minhas, F. A., Carvalho, A. F., Meyer, J. H., Deakin, B., Mulsant, B. H., Husain, N., & Young, A. H. (2020). Minocycline and celecoxib as adjunctive treatments for bipolar depression: A multicentre, factorial design randomised controlled trial. The Lancet. Psychiatry, 7(6), 515–527. doi:10.1016/S2215-0366(20)30138-3
   PubMed Web of Science ®Google Scholar
• Hyman, S. E. (2013). Psychiatric drug development: Diagnosing a crisis. Cerebrum, 2013(5), 5.
   PubMedGoogle Scholar
• Jimerson, D. C., Post, R. M., Carman, J. S., van Kammen, D. P., Wood, J. H., Goodwin, F. K., & Bunney, W. E. Jr. (1979). CSF calcium: Clinical correlates in affective illness and schizophrenia. Biological Psychiatry, 14(1), 37–51.
   PubMed Web of Science ®Google Scholar
• Jobbagy, S., Vitturi, D. A., Salvatore, S. R., Pires, M. F., Rowart, P., Emlet, D. R., Ross, M., Hahn, S., St Croix, C., Wendell, S. G., Subramanya, A. R., Straub, A. C., Tan, R. J., & Schopfer, F. J. (2020). Nrf2 activation protects against lithium-induced nephrogenic diabetes insipidus. JCI Insight, 5(1), e128578. doi:10.1172/jci.insight.128578
   PubMed Web of Science ®Google Scholar
• Kalcev, G., Preti, A., Scano, A., Orrù, G., & Carta, M. G. (2021). Insight into susceptibility genes associated with bipolar disorder: A systematic review. European Review for Medical and Pharmacological Sciences, 25(18), 5701–5724. doi:10.26355/eurrev_202109_26789
   PubMed Web of Science ®Google Scholar
• Karege, F., Schwald, M., Papadimitriou, P., Lachausse, C., & Cissé, M. (2004). The cAMP-dependent protein kinase A and brain-derived neurotrophic factor expression in lymphoblast cells of bipolar affective disorder. Journal of Affective Disorders, 79(1–3), 187–192. doi:10.1016/S0165-0327(02)00463-9
   PubMed Web of Science ®Google Scholar
• Kots, A. Y., Martin, E., Sharina, I. G., & Murad, F. (2009). A short history of cGMP, guanylyl cyclases, and cGMP-dependent protein kinases. Handbook of Experimental Pharmacology. 2009(191), 1–14. doi:10.1007/978-3-540-68964-5_1
   Google Scholar
• Koukopoulos, A., Reginaldi, D., Serra, G., Koukopoulos, A., Sani, G., & Serra, G. (2010). Antimanic and mood-stabilizing effect of memantine as an augmenting agent in treatment-resistant bipolar disorder. Bipolar Disorders, 12(3), 348–349. doi:10.1111/j.1399-5618.2010.00803.x
   PubMed Web of Science ®Google Scholar
• Koukopoulos, A., Sani, G., & Ghaemi, S. N. (2013). Mixed features of depression: Why DSM-5 is wrong (and so was DSM-IV). The British Journal of Psychiatry, 203(1), 3–5. doi:10.1192/bjp.bp.112.124404
   PubMed Web of Science ®Google Scholar
• Koukopoulos, A., Sani, G., Koukopoulos, A. E., Albert, M. J., Girardi, P., & Tatarelli, R. (2006). Endogenous and exogenous cyclicity and temperament in bipolar disorder: Review, new data and hypotheses. Journal of Affective Disorders, 96(3), 165–175. doi:10.1016/j.jad.2006.08.031
   PubMed Web of Science ®Google Scholar
• Kumar, B., Kuhad, A., & Kuhad, A. (2018). Lumateperone: A new treatment approach for neuropsychiatric disorders. Drugs of Today, 54(12), 713–719. doi:10.1358/dot.2018.54.12.2899443
   PubMed Web of Science ®Google Scholar
• Levine, J., Chengappa, K. N., & Reddy, R. (1999). Acute myo-inositol enhances swimming activity in goldfish (short communication). Journal of Neural Transmission, 106(5–6), 433–441. doi:10.1007/s007020050170
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, Dietrich MO, Leke R, Cereser VH, Zanatto V, Kapczinski F, Souza DO, Portela LV, Gentil V. (2007). Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. Biol Psychiatry, 61(2),142–144. doi:10.1016/j.biopsych.2006.03.070
   Google Scholar
• Machado-Vieira, R., Manji, H. K., & Zarate, C. A. Jr. (2011). Potential novel therapeutics for bipolar disorders. Current Topics in Behavioral Neurosciences, 5, 303–329. doi:10.1007/7854_2010_51
   PubMedGoogle Scholar
• Maes, M., Bonifacio, K. L., Morelli, N. R., Vargas, H. O., Moreira, E. G., St Stoyanov, D., Barbosa, D. S., Carvalho, A. F., & Nunes, S. O. V. (2018). Generalized anxiety disorder (GAD) and comorbid major depression with GAD are characterized by enhanced nitro-oxidative stress, increased lipid peroxidation, and lowered lipid-associated antioxidant defenses. Neurotoxicity Research, 34(3), 489–510. doi:10.1007/s12640-018-9906-2
   PubMed Web of Science ®Google Scholar
• Maiorino, M., Roveri, A., Coassin, M., & Ursini, F. (1988). Kinetic mechanism and substrate specificity of glutathione peroxidase activity of ebselen (PZ51). Biochemical Pharmacology, 37(11), 2267–2271. doi:10.1016/0006-2952(88)90591-6
   PubMed Web of Science ®Google Scholar
• Malhi, G. S., & Outhred, T. (2016). Therapeutic mechanisms of lithium in bipolar disorder: Recent advances and current understanding. CNS Drugs, 30(10), 931–949. doi:10.1007/s40263-016-0380-1
   PubMed Web of Science ®Google Scholar
• Malkesman, O., Austin, D. R., Chen, G., & Manji, H. K. (2009). Reverse translational strategies for developing animal models of bipolar disorder. Disease Models & Mechanisms, 2(5–6), 238–245. doi:10.1242/dmm.001628
   PubMed Web of Science ®Google Scholar
• Manji, H. K., Chen, G., Hsiao, J. K., Risby, E. D., Masana, M. I., & Potter, W. Z. (1996). Regulation of signal transduction pathways by mood-stabilizing agents: Implications for the delayed onset of therapeutic efficacy. The Journal of Clinical Psychiatry, 57(Suppl 13), 34–46. discussion 47–8. doi:10.1097/00006842-199909000-00004.
   PubMedGoogle Scholar
• Manji, H. K., & Chen, G. (2002). PKC, MAP kinases and the bcl-2 family of proteins as long- term targets for mood stabilizers. Molecular Psychiatry, 7(Suppl 1), S46–S56. doi:10.1038/sj.mp.4001018
   PubMedGoogle Scholar
• Manji, H. K., McNamara, R., Chen, G., & Lenox, R. H. (1999). Signalling pathways in the brain: Cellular transduction of mood stabilisation in the treatment of manic-depressive illness. The Australian and New Zealand Journal of Psychiatry, 33(Suppl), S65–S83. doi:10.1111/j.1440-1614.1999.00670.x
   PubMedGoogle Scholar
• Mathew, S. J., Manji, H. K., & Charney, D. S. (2008). Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology, 33(9), 2080–2092. Erratum in: Neuropsychopharmacology. 2008;33(9):2300. doi:10.1038/sj.npp.1301652
   PubMed Web of Science ®Google Scholar
• Meltzer, H. L., & Kassir, S. (1982–1983). Abnormal calmodulin-activated CaATPase in manic-depressive subjects. Journal of Psychiatric Research, 17(1), 29–35. doi:10.1016/0022-3956(82)90032-2
   PubMed Web of Science ®Google Scholar
• Mills, G. C. (1957). Hemoglobin catabolism. I. Glutathione peroxidase, an erythrocyte enzyme which protects hemoglobin from oxidative breakdown. The Journal of Biological Chemistry, 229(1), 189–197. doi:10.1016/S0021-9258(18)70608-X
   PubMed Web of Science ®Google Scholar
• Morris, G., Walder, K., Kloiber, S., Amminger, P., Berk, M., Bortolasci, C. C., Maes, M., Puri, B. K., & Carvalho, A. F. (2021). The endocannabinoidome in neuropsychiatry: Opportunities and potential risks. Pharmacological Research, 170, 105729. doi:10.1016/j.phrs.2021.105729
   PubMed Web of Science ®Google Scholar
• Müller, A., Cadenas, E., Graf, P., & Sies, H. (1984). A novel biologically active seleno-organic compound–I. Glutathione peroxidase-like activity in vitro and antioxidant capacity of PZ 51 (Ebselen. Biochemical Pharmacology, 33(20), 3235–3239. doi:10.1016/0006-2952(84)90083-2
   PubMed Web of Science ®Google Scholar
• Newton, D. F., Naiberg, M. R., Andreazza, A. C., Scola, G., Dickstein, D. P., & Goldstein, B. I. (2017). Association of lipid peroxidation and brain-derived neurotrophic factor with executive function in adolescent bipolar disorder. Psychopharmacology, 234(4), 647–656. doi:10.1007/s00213-016-4500-x
   PubMed Web of Science ®Google Scholar
• Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., … Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372, n71. doi:10.1136/bmj.n71
   PubMed Web of Science ®Google Scholar
• Park, L. T., Lener, M. S., Hopkins, M., Iadorola, N., Machado-Vieira, R., Ballard, E., Nugent, A., & Zarate, C. A. Jr. (2017). A Double-blind, placebo-controlled, pilot study of riluzole monotherapy for acute bipolar depression. Journal of Clinical Psychopharmacology, 37(3), 355–358. doi:10.1097/JCP.0000000000000693
   PubMed Web of Science ®Google Scholar
• Polleux, F., Morrow, T., & Ghosh, A. (2000). Semaphorin 3A is a chemoattractant for cortical apical dendrites. Nature, 404(6778), 567–573. doi:10.1038/35007001
   PubMed Web of Science ®Google Scholar
• Quiroz, J. A., Singh, J., Gould, T. D., Denicoff, K. D., Zarate, C. A., & Manji, H. K. (2004). Emerging experimental therapeutics for bipolar disorder: Clues from the molecular pathophysiology. Molecular Psychiatry, 9(8), 756–776. doi:10.1038/sj.mp.4001521
   PubMed Web of Science ®Google Scholar
• Rall, T. W., & Sutherland, E. W. (1958). Formation of a cyclic adenine ribonucleotide by tissue particles. The Journal of Biological Chemistry, 232(2), 1065–1076. doi:10.1016/S0021-9258(19)77422-5
   PubMed Web of Science ®Google Scholar
• Sade, Y., Kara, N. Z., Toker, L., Bersudsky, Y., Einat, H., & Agam, G. (2014). Beware of your mouse strain; differential effects of lithium on behavioral and neurochemical phenotypes in Harlan ICR mice bred in Israel or the USA. Pharmacology, Biochemistry, and Behavior, 124, 36–39. doi:10.1016/j.pbb.2014.05.007
   PubMed Web of Science ®Google Scholar
• Sahar, A., Farhan, A., Bano, S., & Rashid, H. (2020). Docking analysis for identification of lead compound and 3d pharmacophore generation against gsk-3β involved in bipolar disorder. Pakistan Journal of Pharmaceutical Sciences, 33(6), 2547–2552.
   PubMed Web of Science ®Google Scholar
• Sani, G., Napoletano, F., Forte, A. M., Kotzalidis, G. D., Panaccione, I., Porfiri, G. M., Simonetti, A., Caloro, M., Girardi, N., Telesforo, C. L., Serra, G., Romano, S., Manfredi, G., Savoja, V., Tamorri, S. M., Koukopoulos, A. E., Serata, D., Rapinesi, C., Del Casale, A., Nicoletti, F., & Girardi, P. (2012). The wnt pathway in mood disorders. Current Neuropharmacology, 10(3), 239–253. doi:10.2174/157015912803217279
   PubMed Web of Science ®Google Scholar
• Sani, G., Perugi, G., & Tondo, L. (2017). Treatment of Bipolar disorder in a lifetime perspective: Is Lithium still the best choice? Clinical Drug Investigation, 37(8), 713–727. doi:10.1007/s40261-017-0531-2
   PubMed Web of Science ®Google Scholar
• Scola, G., McNamara, R. K., Croarkin, P. E., Leffler, J. M., Cullen, K. R., Geske, J. R., Biernacka, J. M., Frye, M. A., DelBello, M. P., & Andreazza, A. C. (2016). Lipid peroxidation biomarkers in adolescents with or at high-risk for bipolar disorder. Journal of Affective Disorders, 192, 176–183. doi:10.1016/j.jad.2015.12.020
   PubMed Web of Science ®Google Scholar
• Scott, A. I., Perini, A. F., Shering, P. A., & Whalley, L. J. (1991). In-patient major depression: Is rolipram as effective as amitriptyline? European Journal of Clinical Pharmacology, 40(2), 127–129. doi:10.1007/BF00280065
   PubMed Web of Science ®Google Scholar
• Sharma, G., Shin, E. J., Sharma, N., Nah, S. Y., Mai, H. N., Nguyen, B. T., Jeong, J. H., Lei, X. G., & Kim, H. C. (2021). Glutathione peroxidase-1 and neuromodulation: Novel potentials of an old enzyme. Food and Chemical Toxicology, 148, 111945. doi:10.1016/j.fct.2020.111945
   PubMed Web of Science ®Google Scholar
• Sharpley, A. L., Williams, C., Holder, A. A., Godlewska, B. R., Singh, N., Shanyinde, M., MacDonald, O., & Cowen, P. J. (2020). A phase 2a randomised, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania. Psychopharmacology, 237(12), 3773–3782. doi:10.1007/s00213-020-05654-1
   PubMedGoogle Scholar
• Shin, E. J., Nguyen, B. T., Jeong, J. H., Hoai Nguyen, B. C., Tran, N. K. C., Sharma, N., Kim, D. J., Nah, S. Y., Lichtstein, D., Nabeshima, T., & Kim, H. C. (2021). Ouabain inhibitor rostafuroxin attenuates dextromethorphan-induced manic potential. Food and Chemical Toxicology, 158, 112657. doi:10.1016/j.fct.2021.112657
   PubMed Web of Science ®Google Scholar
• Siegel, A. N., Rodrigues, N., Nasri, F., Wilkialis, L., Lipsitz, O., Lee, Y., Gill, H., Subramaniapillai, M., Phan, L., Majeed, A., Lui, L. M. W., Rashidian, H., Ho, R., Toma, S., Goldstein, B. I., Mansur, R. B., McIntyre, R. S., & Rosenblat, J. D. (2021). Novel therapeutic targets in mood disorders: Pentoxifylline (PTX) as a candidate treatment. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 104, 110032. doi:10.1016/j.pnpbp.2020.110032
   PubMed Web of Science ®Google Scholar
• Sies, H. (1993). Ebselen, a selenoorganic compound as glutathione peroxidase mimic. Free Radical Biology & Medicine, 14(3), 313–323. doi:10.1016/0891-5849(93)90028-s
   PubMed Web of Science ®Google Scholar
• Smith, M., Drummond, G. I., & Khorana, H. G. (1961). Cyclic phosphates. IV.1 Ribonucleoside-3′,5′ cyclic phosphates. A general method of synthesis and some properties. Journal of the American Chemical Society, 83(3), 698–706. doi:10.1021/ja01464a039
   Web of Science ®Google Scholar
• Stewart, R. J., Chen, B., Dowlatshahi, D., MacQueen, G. M., & Young, L. T. (2001). Abnormalities in the cAMP signaling pathway in post-mortem brain tissue from the Stanley Neuropathology Consortium. Brain Research Bulletin, 55(5), 625–629. doi:10.1016/S0361-9230(01)00524-X
   PubMed Web of Science ®Google Scholar
• Sutherland, E. W., & Rall, T. W. (1958). Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles. The Journal of Biological Chemistry, 232(2), 1077–1091. doi:10.1016/S0021-9258(19)77423-7
   PubMed Web of Science ®Google Scholar
• Torphy, T. J., DeWolf, W. E., Jr, Green, D. W., & Livi, G. P. (1993). Biochemical characteristics and cellular regulation of phosphodiesterase IV. Agents and Actions. Supplements, 43(Suppl), 51–71. doi:10.1007/978-3-0348-7324-6_5
   PubMedGoogle Scholar
• Versace, A., Andreazza, A. C., Young, L. T., Fournier, J. C., Almeida, J. R., Stiffler, R. S., Lockovich, J. C., Aslam, H. A., Pollock, M. H., Park, H., Nimgaonkar, V. L., Kupfer, D. J., & Phillips, M. L. (2014). Elevated serum measures of lipid peroxidation and abnormal prefrontal white matter in euthymic bipolar adults: Toward peripheral biomarkers of bipolar disorder. Molecular Psychiatry, 19(2), 200–208. doi:10.1038/mp.2012.188
   PubMed Web of Science ®Google Scholar
• Villoutreix, B. O. (2021). Post-pandemic drug discovery and development: Facing present and future challenges. Frontiers in Drug Discovery, 1, 728469. doi:10.3389/fddsv.2021.728469
   Google Scholar
• Wachtel, H. (1983). Potential antidepressant activity of rolipram and other selective cyclic adenosine 3¢,5¢-mono-phosphate phosphodiesterase inhibitors. Neuropharmacology, 22(3), 267–272. doi:10.1016/0028-3908(83)90239-3
   PubMed Web of Science ®Google Scholar
• Won, E., & Kim, Y. K. (2017). An oldie but goodie: Lithium in the treatment of bipolar disorder through neuroprotective and neurotrophic mechanisms. International Journal of Molecular Sciences, 18(12), 2679. doi:10.3390/ijms18122679
   PubMed Web of Science ®Google Scholar
• Xia, Y., Wang, C. Z., Liu, J., Anastasio, N. C., & Johnson, K. M. (2008). Lithium protection of phencyclidine-induced neurotoxicity in developing brain: The role of phosphatidylinositol-3 kinase/Akt and mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signaling pathways. The Journal of Pharmacology and Experimental Therapeutics, 326(3), 838–848. doi:10.1124/jpet.107.133272
   PubMed Web of Science ®Google Scholar
• Xiong, Y., Fan, J., Kitabi, E., Zhang, X., Bi, Y., Grimstein, M., Yang, Y., Earp, J. C., Zheng, N., Liu, J., Wang, Y., & Zhu, H. (2022). Model-informed drug development approaches to assist new drug development in the COVID-19 pandemic. Clinical Pharmacology and Therapeutics, 111(3), 572–578. doi:10.1002/cpt.2491
   PubMed Web of Science ®Google Scholar
• Yohn, S. E., Foster, D. J., Covey, D. P., Moehle, M. S., Galbraith, J., Garcia-Barrantes, P. M., Cho, H. P., Bubser, M., Blobaum, A. L., Joffe, M. E., Cheer, J. F., Jones, C. K., Lindsley, C. W., & Conn, P. J. (2020). Activation of the mGlu1 metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M4 muscarinic receptor allosteric modulators. Molecular Psychiatry, 25(11), 2786–2799. doi:10.1038/s41380-018-0206-2
   PubMed Web of Science ®Google Scholar
• Zaccolo, M., & Movsesian, M. A. (2007). cAMP and cGMP signaling cross-talk: Role of phosphodiesterases and implications for cardiac pathophysiology. Circulation Research, 100(11), 1569–1578. doi:10.1161/CIRCRESAHA.106.144501
   PubMed Web of Science ®Google Scholar
• Zarate, C., Jr, Machado-Vieira, R., Henter, I., Ibrahim, L., Diazgranados, N., & Salvadore, G. (2010). Glutamatergic modulators: The future of treating mood disorders? Harvard Review of Psychiatry, 18(5), 293–303. doi:10.3109/10673229.2010.511059
   PubMed Web of Science ®Google Scholar
• Zeller, E., Stief, H. J., Pflug, B., & Sastre-y-Hernández, M. (1984). Results of a phase II study of the antidepressant effect of rolipram. Pharmacopsychiatry, 17(6), 188–190. doi:10.1055/s-2007-1017435
   PubMed Web of Science ®Google Scholar
• Zhou, Y. Q., Liu, D. Q., Chen, S. P., Sun, J., Zhou, X. R., Xing, C., Ye, D. W., & Tian, Y. K. (2019). The role of CXCR3 in neurological diseases. Current Neuropharmacology, 17(2), 142–150. doi:10.2174/1570159X15666171109161140
   PubMed Web of Science ®Google Scholar